Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V4WT
|
|||
| Former ID |
DIB020644
|
|||
| Drug Name |
paxilline
|
|||
| Synonyms |
4b-Hydroxy-2-(1-hydroxy-1-methylethyl)-12b,12c-dimethyl-5,6,6a,7,12,12b,12c,13,14,14a-decahydro-2H-chromeno[5',6':6,7]indeno[1,2-b]indol-3(4bH)-one; paxillin; AC1L1IR1; GTPL2309; BDBM86263; CTK7H1286; ACNHBCIZLNNLRS-UHFFFAOYSA-N; NCGC00168476-01; CAS_57186-25-1; hydroxy-(1-hydroxy-1-methyl-ethyl)-dimethyl-[ ]one; 4b-Hydroxy-2-(1-hydroxy-1-methylethyl)-12b,12c-dimethyl-5,6,6a,7,12,12b,12c,13,14,14a-decahydro-2H-chromeno[5',6':6,7]indeno[1,2-b]indol-3(4bh)-one #
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H33NO4
|
|||
| Canonical SMILES |
CC12CCC3C(=CC(=O)C(O3)C(C)(C)O)C1(CCC4C2(C5=C(C4)C6=CC=CC=C6N5)C)O
|
|||
| InChI |
1S/C27H33NO4/c1-24(2,30)23-20(29)14-18-21(32-23)10-11-25(3)26(4)15(9-12-27(18,25)31)13-17-16-7-5-6-8-19(16)28-22(17)26/h5-8,14-15,21,23,28,30-31H,9-13H2,1-4H3/t15-,21-,23-,25+,26+,27+/m0/s1
|
|||
| InChIKey |
ACNHBCIZLNNLRS-UBGQALKQSA-N
|
|||
| CAS Number |
CAS 57186-25-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:34907
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Charybdotoxin receptor beta-4 (BKbeta4) | Target Info | Blocker (channel blocker) | [2] |
| Oxysterols receptor LXR-alpha (NR1H3) | Target Info | Agonist | [3] | |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Vascular smooth muscle contraction | ||||
| Insulin secretion | ||||
| Salivary secretion | ||||
| Pancreatic secretion | ||||
| PPAR signaling pathway | ||||
| Non-alcoholic fatty liver disease (NAFLD) | ||||
| Hepatitis C | ||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
| Reactome | cGMP effects | |||
| WikiPathways | Potassium Channels | |||
| Platelet homeostasis | ||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Nuclear Receptors Meta-Pathway | ||||
| PPAR Alpha Pathway | ||||
| Liver X Receptor Pathway | ||||
| Adipogenesis | ||||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2309). | |||
| REF 2 | Paxilline inhibition of the alpha-subunit of the high-conductance calcium-activated potassium channel. Neuropharmacology. 1996;35(7):963-8. | |||
| REF 3 | A natural product ligand of the oxysterol receptor, liver X receptor. J Pharmacol Exp Ther. 2003 Oct;307(1):291-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.